Attention is focused on expanding insurance coverage for the first-line treatment of the anticancer drug Leclaza. According to related industries, Yuhan Corporation's 3rd generation EGFR TKI Leclaza will be scheduled for the HIRA on the 30th. The specific indication is 'primary treatment for EGFR active non-small cell lung cancer'. Leclaza obtained approval from the Ministry of Food and Drug Safety for the indication in June. If it is presented to the review committee, the evaluation discussion will proceed within two months of approval. This drug passed the review committee about a month after January 2021, when it was first approved as a second-line treatment, and was listed in July of the same year. As a domestic